Receive our newsletter – data, insights and analysis delivered to you
  1. News
May 16, 2017

Boston Scientific completes acquisition of Symetis for $435m

Boston Scientific has completed the $435m purchase of Switzerland-based firm Symetis, under the definitive agreement signed by the companies in March.

Boston Scientific has completed the $435m purchase of Switzerland-based firm Symetis, under the definitive agreement signed by the companies in March.

The transaction expands Boston Scientific’s structural heart portfolio and enhances its treatment options for patients suffering from valvular heart disease.

Symetis focuses on the development of minimally invasive transcatheter aortic valve implantation (TAVI) devices, and will now be integrated into the interventional cardiology division of Boston Scientific.

With the acquisition now complete, Boston Scientific plans to immediately commence the sale of Symetis’ ACURATE TA and ACURATE neo/TF valve systems in markets outside the US.

"This valve offering, along with our left atrial appendage closure device, uniquely positions us to advance structural heart solutions for patients, while fueling continued growth for the company."

Boston Scientific executive vice-president and global chief medical officer Ian Meredith said: "Adding the ACURATE family of valve products to our structural heart portfolio presents us with the opportunity to provide two distinctly different but complementary TAVI platforms.

"Enabling implanting physicians and hospitals to treat the broadest range of patients and aortic valve anatomies, this valve offering, along with our left atrial appendage closure device, uniquely positions us to advance structural heart solutions for patients, while fueling continued growth for the company."

Content from our partners
“Everything is custom”: Behind the scenes of medical wire solutions
The added value of Qarad’s multilingual freephone service to their eIFU solution
Small and simple: how medical device manufacturers select materials

Similar to Boston Scientific’s LOTUS valve system, the ACURATE valves are being developed for the treatment of severe and symptomatic aortic valve stenosis patients, who have a high risk of surgical valve replacement.

Boston Scientific intends to continue the development of the next-generation ACURATE neo/AS valve system, which is currently under evaluation in a clinical trial being conducted to support a future CE mark application. 

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU